כמות מזומנים למניה alimerasciences.com (ALIM)

Alimera Sciences, Inc. - לוגו גרפי של המנפיק ALIM

Is it worth investing in Alimera Sciences (ALIM), given the profit dependence on sales of retinal edema treatments and market competition? The calculated cash per share confirms the company's resilience, while the 0.20 value serves as a baseline liquidity indicator. This is supported by the use of proprietary Iluvien implants, which create a stable sales channel. Ultimately, the integration of this therapy into ophthalmological practice ensures long-term vision preservation for patients.

alimerasciences.com (ALIM): מזומנים למניה אחת מ-04.07.2022 עד 21.09.2024

פילוחי מדדים מקיפים ואנליטיקה עבור alimerasciences.com (ALIM)

- מחיר שוק ויעדי מחיר של אנליסטים:
- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח מסכם של החברה:Alimera Sciences
מוצר המיוצר על ידי Alimera Sciences

Cash per share determines the portion of liquid assets attributable to a single security, allowing for an assessment of the business's real intrinsic value. Monitoring this metric protects the investor from management errors and unjustified price inflation. By analyzing the trend of the cash cushion per share, one can identify insolvency risks. For Alimera Sciences (ALIM), this reserve is critical in the event of losing sales markets due to sanctions. Liquidity ensures the company's stability amidst the disruption of global logistics chains.